Peer-reviewed veterinary case report
High-risk molecular types of malignant mammary tumors in female dogs
By Zamani-Ahmadmahmudi, Mohamad et al.·Published in Veterinary and comparative oncology·2023·Department of Clinical Science·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Molecular phenotyping of malignant canine mammary tumours: Detection of high-risk group and its relationship with clinicomolecular characteristics.
- Species:
- dog
Plain-English summary
A study found that malignant mammary tumors are the most common cancer in female dogs, particularly affecting those with certain high-risk characteristics. Researchers analyzed tumor samples from 113 dogs and identified four different molecular subtypes, with one subtype (C5) linked to aggressive features like lymphatic invasion and shorter survival times. This high-risk group was identified using a specific gene signature that could predict poor outcomes. The findings suggest that understanding these molecular characteristics can help veterinarians better assess and treat dogs with mammary tumors.
People also search for: dog mammary tumor treatment · female dog cancer symptoms · canine cancer survival rates
Abstract
Canine mammary gland tumours (CMTs) constitute the most common cancer in female dogs and comprise approximately 50% of all canine cancers. With the advent of high-throughput technologies such as microarray and next-generation sequencing, the molecular phenotyping (classification) of various cancers has been extensively developed. The present study used a canine RNA-sequencing dataset, namely GSE119810, to classify 113 malignant CMTs and 64 matched normal samples via an unsupervised hierarchical algorithm with a view to evaluating the association between the resulting subtypes (clusters) (n = 4) and clinical and molecular characteristics. Finally, a molecular classifier was developed, and it detected 1 high-risk molecular subtype in the training dataset (GSE119810) and 2 independent validation datasets (GSE20718 and GSE22516). Our results revealed four molecular subtypes (C2-C5) in malignant CMTs. Furthermore, the normal samples constituted a distinct group in the clustering analysis. Marked significant associations were observed between the molecular subtypes (especially C5) and clinical/molecular features, including positive lymphatic invasion, high tumour grades, histopathology diagnoses, short survival and high TP53 mutation rates (ps <.05). The high-risk subtype (C5) was further characterized through the development of a cell cycle-based gene signature, which comprised 37 proliferation-related genes according to the support vector machine algorithm. This signature identified the high-risk group in both training and validation datasets (ps <.001). In the validation analysis, our potential classifier robustly predicted patients with positive lymphatic invasion, metastases and short survival.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36251017/